Description du projet
Administrer un nanomédicament personnalisé dans le microenvironnement de la tumeur
Il existe de nombreuses maladies dont les besoins médicaux ne sont pas satisfaits, comme le cancer. La nanotechnologie est apparue comme une solution prometteuse pour encapsuler des médicaments et augmenter leur stabilité et leur biodistribution. Le projet ICARUS, financé par l’UE, entend améliorer l’efficacité et le résultat thérapeutique des nanomédicaments personnalisés contre le cancer. Ces nanomédicaments sont biodégradables et présentent un excellent profil pharmacocinétique. Au cours du projet ICARUS, les chercheurs envisagent de développer des méthodologies analytiques innovantes de pointe qui permettront de comprendre la distribution et le comportement de ces nanomédicaments dans le microenvironnement de la tumeur. Les résultats ouvriront la voie pour des médicaments mieux tolérés que les modalités de traitement habituelles.
Objectif
Cristal Therapeutics (CT) is an innovative SME based in the Netherlands dedicated to the creation of the next generation of targeted nanomedicines (NM). CT has developed CriPec, a nanoparticle technology that can entrap a wide range of drugs, transforming them into custom-made NM. CriPec-based products have demonstrated excellent pharmacokinetics and tumour accumulation as well as highly improved safety, both in laboratory and patient settings. However, the full therapeutic potential of CriPec has not been obtained due to a lack of understanding of its tumour microenvironment (TME) microdistribution and behaviour, hindered by the lack of highly specific (bio)analytical expertise within Cristal Therapeutics.
ICARUS will enable CT to solidify its position as an innovative SME and provide them a competitive edge through hiring an Innovation Associate (IA). The envisioned IA will develop and implement state-of-art (bio)analytical methodologies (including advanced MALDI-techniques) that have not been exploited in the field of NM until now, and that will provide CT with essential insights that will guide the composition optimisation of all CriPec-based products.
Furthermore, the ICARUS project is heavily focused around the training of the IA, thereby greatly improving his/her career development. A training programme tailored to his/her specific needs and personal career development plan will be developed, allowing the IA to:
• Gain novel skills and experience on every aspect of the development of nanoparticles, encompassing the required multidisciplinary expertise from several fields;
• Gain innovation and business related skills in a multidisciplinary setting.
Champ scientifique
Programme(s)
Régime de financement
CSA-LSP - Coordination and support action Lump sumCoordinateur
6229 EV MAASTRICHT
Pays-Bas
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.